October 20, 2022Open Access

Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death

Key Points

Key points are not available for this paper at this time.

Abstract

Our real-world study found high and durable two- and three-dose inactivated VE against Omicron-associated severe/critical illness and death across all age groups, but lower effectiveness against Omicron infection, which reinforces the critical importance of full-series vaccination and timely booster dose administration for all eligible individuals.

Bookmark

View Full Paper

Cite This Study

Huang et al. (Thu,) studied this question.

synapsesocial.com/papers/69dd4429fb7610310c1016b4 https://doi.org/https://doi.org/10.1186/s12916-022-02606-8

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Limited Cross-Variant Immunity after Infection with the SARS-CoV-2 Omicron Variant Without Vaccination2022 · 35 citations
2mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar2021 · 444 citations
3BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting2021 · 2,810 citations
4Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies2021 · 2,113 citations
5Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil2022 · 115 citations

Bookmark

View Full Paper